Published in AIDS on October 22, 1999
Genotyping of Toxoplasma gondii strains from immunocompromised patients reveals high prevalence of type I strains. J Clin Microbiol (2005) 1.78
Effectiveness of highly active antiretroviral therapy among HIV-1 infected women. J Epidemiol Community Health (2002) 1.42
Distinguishing efficacy, individual effectiveness and population effectiveness of therapies. AIDS (2000) 1.11
Quality of data collection in a large HIV observational clinic database in sub-Saharan Africa: implications for clinical research and audit of care. J Int AIDS Soc (2011) 1.06
Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. Haematologica (2011) 1.00
Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? AIDS (2008) 0.91
Human immunodeficiency virus on the web: a guided tour. Clin Infect Dis (2000) 0.88
Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infection. AIDS Res Hum Retroviruses (2012) 0.86
Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999. Sex Transm Infect (2002) 0.86
Comparative Effectiveness of First Antiretroviral Regimens in Clinical Practice Using a Causal Approach. Medicine (Baltimore) (2015) 0.82
Does HAART efficacy translate to effectiveness? Evidence for a trial effect. PLoS One (2011) 0.82
Using multiple types of studies in systematic reviews of health care interventions--a systematic review. PLoS One (2013) 0.81
Surveillance monitoring for safety of in utero antiretroviral therapy exposures: current strategies and challenges. Expert Opin Drug Saf (2016) 0.79
HIV seroconversion interval and demographic characteristics: no evidence of selection bias. Sex Transm Infect (2001) 0.78
The effect of adherence to guidelines for initial antiretroviral therapy on 1-year outcomes: a French cohort study. BMC Infect Dis (2014) 0.75
Immunoblot profile as predictor of toxoplasmic encephalitis in patients infected with human immunodeficiency virus. Clin Diagn Lab Immunol (2001) 0.75
Autoimmune diseases and HIV infection: A cross-sectional study. Medicine (Baltimore) (2017) 0.75
Immunologic response in treatment-naïve HIV-2-infected patients: the IeDEA West Africa cohort. J Int AIDS Soc (2016) 0.75
The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med (2001) 37.70
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ (2001) 20.65
The hazards of scoring the quality of clinical trials for meta-analysis. JAMA (1999) 17.00
Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol (2001) 12.72
Misleading meta-analysis. BMJ (1995) 11.94
Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol (2000) 7.95
Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet (2003) 7.94
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet (1998) 7.53
Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ (2001) 7.13
Who benefits from medical interventions? BMJ (1994) 5.58
Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet (1999) 4.83
Early enteral feeding versus "nil by mouth" after gastrointestinal surgery: systematic review and meta-analysis of controlled trials. BMJ (2001) 4.47
Interleukin-2 therapy in patients with HIV infection. N Engl J Med (2009) 4.38
Socioeconomic differentials in wealth and health. BMJ (1993) 4.32
Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med (2000) 3.95
Magnesium and myocardial infarction. Lancet (1994) 3.74
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med (2008) 3.68
Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS (1999) 3.67
Grey literature in meta-analyses of randomized trials of health care interventions. Cochrane Database Syst Rev (2007) 3.51
HIV and male circumcision--a systematic review with assessment of the quality of studies. Lancet Infect Dis (2005) 3.49
Reporting on quality of life in randomised controlled trials: bibliographic study. BMJ (1998) 3.37
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA (1999) 3.34
Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives. Health Technol Assess (2001) 3.32
Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet (2003) 3.23
Smoking and health promotion in Nazi Germany. J Epidemiol Community Health (1994) 3.20
HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA (2001) 2.95
Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS (2002) 2.90
Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS (1998) 2.90
Do all men attending departments of genitourinary medicine need to be screened for non-gonococcal urethritis? Int J STD AIDS (2002) 2.81
Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet (1999) 2.80
What is known about the prevention of congenital toxoplasmosis? Lancet (1990) 2.78
Funding clinical research. Lancet (1999) 2.63
Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med (2000) 2.49
An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet (2003) 2.43
Improved diagnosis of Pneumocystis carinii infection by polymerase chain reaction on induced sputum and blood. Lancet (1992) 2.40
The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess (2005) 2.38
The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med (2006) 2.38
The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Praventivmed (1994) 2.38
Genital Chlamydia trachomatis infections in Uppsala County, Sweden, 1985-1993: declining rates for how much longer? Sex Transm Dis (1995) 2.36
Commentary: understanding it all--health, meta-theories, and mortality trends. BMJ (1997) 2.35
Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev (2003) 2.32
Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis (2004) 2.26
Are randomised controlled trials in the BMJ different? BMJ (2001) 2.26
Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis (2001) 2.24
Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection. Health Technol Assess (2007) 2.23
Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis (2001) 2.19
Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med (1999) 2.17
Tuberculosis in HIV programmes in lower-income countries: practices and risk factors. Int J Tuberc Lung Dis (2011) 2.15
Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS (2000) 2.14
Patterns of disclosure and perceptions of the human immunodeficiency virus in infected elementary school-age children. Arch Pediatr Adolesc Med (1997) 2.14
Hip fractures and fluoridation in Utah's elderly population. JAMA (1992) 2.13
AIDS across Europe, 1994-98: the EuroSIDA study. Lancet (2000) 2.13
Update on Pneumocystis carinii f. sp. hominis typing based on nucleotide sequence variations in internal transcribed spacer regions of rRNA genes. J Clin Microbiol (1998) 2.11
Immobilized proteins in buffer imaged at molecular resolution by atomic force microscopy. Biophys J (1990) 2.04
Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood (2001) 1.98
Cardio- and cerebrovascular events in HIV-infected persons. AIDS (2004) 1.98
Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group. Int J Epidemiol (1997) 1.97
Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group. Lancet (1999) 1.95
The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Clin Infect Dis (2013) 1.91
Role of Mycoplasma genitalium and Ureaplasma urealyticum in acute and chronic nongonococcal urethritis. Clin Infect Dis (2001) 1.89
Smoking and death. Public health measures were taken more than 40 years ago. BMJ (1995) 1.85
Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. The HIV Infection in Newborns French Collaborative Study Group. Am J Epidemiol (1995) 1.84
The chlamydia screening studies: rationale and design. Sex Transm Infect (2004) 1.83
Socioeconomic differences in mortality in Britain and the United States. Am J Public Health (1992) 1.71
Loss to follow-up in an international, multicentre observational study. HIV Med (2008) 1.70
Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science (2000) 1.70
Meta-analysis. Unresolved issues and future developments. BMJ (1998) 1.69
Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. Clin Infect Dis (2001) 1.68
Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials. Heart (2005) 1.61
Incommunicable knowledge? Interpreting and applying the results of clinical trials and meta-analyses. J Clin Epidemiol (1998) 1.60
Incidence of severe reproductive tract complications associated with diagnosed genital chlamydial infection: the Uppsala Women's Cohort Study. Sex Transm Infect (2006) 1.59
Calcium signalling in cardiac muscle: refractoriness revealed by coherent activation. Nat Cell Biol (1999) 1.54
Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load(1). Obstet Gynecol (2000) 1.53
Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statins 1990 to 2001. Heart (2003) 1.53
The case for indicator condition-guided HIV screening. HIV Med (2013) 1.48
Meta-analysis. Beyond the grand mean? BMJ (1997) 1.48
[The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting of observational studies]. Internist (Berl) (2008) 1.47
Human versus porcine insulin gone wrong. Diabetes Care (1992) 1.44
Misleading meta-analysis. BMJ (1995) 1.43
Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. Br J Cancer (2012) 1.41
Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective. Vox Sang (2001) 1.40
Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires. Arch Intern Med (1990) 1.40
Meta-analysis: is moving the goal post the answer? Lancet (1998) 1.39
Lack of association between human leukocyte antigens and the anti-Hu syndrome in patients with small-cell lung cancer. Neurology (1998) 1.39
Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. Clin Infect Dis (2016) 1.39
The European-Australian Collaborative Group Study 017 of zidovudine versus placebo. AIDS (1994) 1.38
Biological properties of HIV isolates in primary HIV infection: consequences for the subsequent course of infection. AIDS (1993) 1.36
Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. Blood (1999) 1.36
A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. J Acquir Immune Defic Syndr (1999) 1.35
Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses (2005) 1.34
Identification of Pneumocystis carinii chromosomes and mapping of five genes. Infect Immun (1990) 1.34
Adolescent diet and breast cancer in Utah. Cancer Res (1989) 1.32
Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome. AIDS (1996) 1.32
Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. J Infect Dis (2004) 1.31
Diagnostic use of PCR for detection of Pneumocystis carinii in oral wash samples. J Clin Microbiol (1998) 1.31